Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Oncologist. 2020 Jul;25(7):e1031-e1041. doi: 10.1634/theoncologist.2019-0797. Epub 2020 Mar 17.
The calculation of the tumor burden score (TBS) is not perfect because the bilobar spread of colorectal liver metastasis (CRLM) is neglected. The identification of an ideal prognostic scoring system for CRLM remains controversial.
Patients who underwent curative intent liver resection for CRLM from one medical center were enrolled in cohort 1 (787 patients) and cohort 2 (162 patients). Tumor relapse-free survival (RFS) was the main outcome. A Cox regression model was used to identify independent predictors of prognosis. The time-dependent area under the curve, calibration curve, and C-index were employed to validate the predictive ability of the survival model.
Modified TBS (mTBS) was established by a mathematical equation with parameters including CRLM size, CRLM number, and unilobar or bilobar metastasis. Five preoperative predictors of worse RFS were identified in cohort 1 and incorporated into the Comprehensive Evaluation of Relapse Risk (CERR) score: KRAS/NRAS/BRAF-mutated tumor (1 point); node-positive primary (1 point); extrahepatic disease (1 point); carcinoembryonic antigen level > 200 ng/mL or carbohydrate antigen 19-9 (CA19-9) >200 U/mL (1 point); and mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients in cohort 1 were stratified by their CERR score into risk groups: the high-risk group (CERR score 4 or more), the medium-risk group (CERR score 2-3), and the low-risk group (CERR score 0-1). Importantly, internal validation in cohort 1 and further validation in cohort 2 both showed the superior discriminatory capacity of the CERR score.
mTBS should be promoted. The CERR score is a powerful prognostic tool that can help determine optimal clinical management strategies.
This work resulted in the successful modification of the tumor burden score and development of a comprehensive and practical prognostic scoring system-the Comprehensive Evaluation of Relapse Risk (CERR) score. The CERR score, with a better prognostic discriminatory ability, outperformed the Fong score. Perhaps more importantly, the CERR score is a powerful prognostic tool because it unified the most consistently reported prognostic factors. Therefore, the CERR score can assist doctors in determining optimal clinical management strategies.
肿瘤负担评分(TBS)的计算并不完善,因为结直肠癌肝转移(CRLM)的双侧播散被忽略了。目前对于 CRLM,仍缺乏理想的预后评分系统。
本研究纳入了单中心行根治性肝切除术的 CRLM 患者,将其分为队列 1(787 例患者)和队列 2(162 例患者)。主要研究终点为肿瘤无复发生存(RFS)。采用 Cox 回归模型识别独立预后预测因素。采用时间依赖性曲线下面积、校准曲线和 C 指数来验证生存模型的预测能力。
通过一个包含 CRLM 大小、CRLM 数量以及单侧或双侧转移的数学方程建立了改良 TBS(mTBS)。在队列 1 中发现了 5 个预测 RFS 较差的术前预测因素,并纳入了综合复发风险评估(CERR)评分:KRAS/NRAS/BRAF 突变肿瘤(1 分);阳性淋巴结(1 分);肝外疾病(1 分);癌胚抗原水平>200ng/ml 或碳水化合物抗原 19-9(CA19-9)>200U/ml(1 分);mTBS 为 5-11 分(1 分)或 12 分以上(2 分)。队列 1 中的患者根据 CERR 评分分为高危组(CERR 评分 4 分或更高)、中危组(CERR 评分 2-3 分)和低危组(CERR 评分 0-1 分)。重要的是,队列 1 中的内部验证以及队列 2 中的进一步验证均表明 CERR 评分具有更高的区分能力。
mTBS 应得到推广。CERR 评分是一种强大的预后工具,可以帮助确定最佳的临床管理策略。
本研究成功改良了肿瘤负担评分并制定了一种全面实用的预后评分系统——综合复发风险评估(CERR)评分。CERR 评分具有更好的预后区分能力,优于 Fong 评分。更重要的是,CERR 评分是一种强大的预后工具,因为它统一了最一致报道的预后因素。因此,CERR 评分可以帮助医生确定最佳的临床管理策略。